Amplification and Selection of Antimicrobial Resistance in the Intestine II
- Registration Number
- NCT03140826
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
Stool samples will be collected from two groups of neutropenic patients in the case that a therapy with either meropenem or piperacillin/tazobactam is needed due to a suspected infection. The intestinal resistome will be determined and quantified using shotgun metagenomics. Based on this, regression models will be used to determine the actual selection pressure caused by these drugs, and both selective forces will be compared. The results will reveal if there is a drug that causes a lower selection pressure compared to the other. The study aims to generate knowledge that is required to design effective antibiotic stewardship programs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Patients with hemato-oncological disease in neutropenia or with expected neutropenia
- Need for treatment with meropenem or piperacillin-tazobactam
- pregnancy
- HIV, HBV, HCV
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Meropenem arm meropenem Patients receiving meropenem to treat an infection.
- Primary Outcome Measures
Name Time Method Antibiotic Selection Pressure under treatment, max. 10 days Degree of the change of the intestinal resistome.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Institute of Medical Microbiology and Hygiene, University Hospital of Tuebingen
🇩🇪Tuebingen, Germany
University Hospital Cologne
🇩🇪Cologne, Germany